Search research articles
Contact Us
Filters
Showing results (1-10 of 270) with videos related to
Page
of 27
Sort By:
Journal of Lipid Research
|
June 21, 2013
High density lipoprotein structure, function, and metabolism: a new Thematic Series
Kerry-Anne Rye
Clinical and Experimental Nephrology
|
September 21, 2013
Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease
Kerry-Anne Rye
Trends in Pharmacological Sciences
|
November 18, 2011
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Philip Barter, Kerry-Anne Rye
Nature Clinical Practice. Cardiovascular Medicine
|
May 27, 2006
Are we lowering LDL cholesterol sufficiently?
Philip Barter, Kerry-Anne Rye
Clinical Science (London, England : 1979)
|
December 17, 2008
High-density lipoproteins, inflammation and oxidative stress
Fatiha Tabet, Kerry-Anne Rye
Journal of Lipid Research
|
December 4, 2018
A Letter from the Editors-in-Chief
Kerry-Anne Rye, Nick Davidson
Nature Reviews. Cardiology
|
April 8, 2016
Coronary artery disease: Scavenger receptor class B1--a target to reduce CHD risk?
Philip J Barter, Kerry-Anne Rye
Circulation
|
September 20, 2006
Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins
Philip J Barter, Kerry-Anne Rye
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 1, 2003
Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I
Kerry-Anne Rye, Philip J Barter
Journal of Lipid Research
|
May 3, 2012
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
Philip J Barter, Kerry-Anne Rye
Page
of 27
Search research articles
Search
Showing results (1-10 of 270) with videos related to
Sort By:
Page
of 27
Journal of Lipid Research
|
June 21, 2013
High density lipoprotein structure, function, and metabolism: a new Thematic Series
Kerry-Anne Rye
Clinical and Experimental Nephrology
|
September 21, 2013
Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease
Kerry-Anne Rye
Trends in Pharmacological Sciences
|
November 18, 2011
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Philip Barter, Kerry-Anne Rye
Nature Clinical Practice. Cardiovascular Medicine
|
May 27, 2006
Are we lowering LDL cholesterol sufficiently?
Philip Barter, Kerry-Anne Rye
Clinical Science (London, England : 1979)
|
December 17, 2008
High-density lipoproteins, inflammation and oxidative stress
Fatiha Tabet, Kerry-Anne Rye
Journal of Lipid Research
|
December 4, 2018
A Letter from the Editors-in-Chief
Kerry-Anne Rye, Nick Davidson
Nature Reviews. Cardiology
|
April 8, 2016
Coronary artery disease: Scavenger receptor class B1--a target to reduce CHD risk?
Philip J Barter, Kerry-Anne Rye
Circulation
|
September 20, 2006
Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins
Philip J Barter, Kerry-Anne Rye
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 1, 2003
Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I
Kerry-Anne Rye, Philip J Barter
Journal of Lipid Research
|
May 3, 2012
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
Philip J Barter, Kerry-Anne Rye
Page
of 27